Page last updated: 2024-11-13

delanzomib

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID24800541
CHEMBL ID270515
CHEBI ID141530
SCHEMBL ID555047
MeSH IDM0586918

Synonyms (59)

Synonym
CHEMBL270515 ,
nph007098
cip-18770
nph 007098
ct 47098
cip 18770
nph-007098
cep 18770
[(1r)-3-methyl-1-({n-[(6-phenylpyridin-2-yl)carbonyl]-l-threonyl}amino)butyl]boronic acid
delanzomib ,
delanzomibum
847499-27-8
ct-47098
CHEBI:141530
cep-18770 ,
[(1r)-1-[[(2s,3r)-3-hydroxy-1-oxo-2-[[oxo-(6-phenyl-2-pyridyl)methyl]amino]butyl]amino]-3-methylbutyl]boronic acid
boronic acid, ((1r)-1-(((2s,3r)-3-hydroxy-1-oxo-2-(((6-phenyl-2-pyridinyl)carbonyl)amino)butyl)amino)-3-methylbutyl)-
[(1r)-1-[[(2s,3r)-3-hydroxy-2-[(6-phenylpyridin-2-yl)carbonylamino]butanoyl]amino]-3-methyl-butyl]boronic acid
D10110
delanzomib (usan)
[(1r)-1-[[(2s,3r)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid
(r)-1-((2s,3r)-3-hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutylboronic acid
bdbm50329819
6if28942wo ,
delanzomib [usan:inn]
unii-6if28942wo
NCGC00346469-01
delanzomib [inn]
delanzomib [usan]
((1r)-1-((2s,3r)-3-hydroxy-2-(6-phenylpyridine-2-carboxamido)butanamido)-3-methylbutyl)boronic acid
b-((1r)-1-((n-((6-phenylpyridin-2-yl)carbonyl)-l-threonyl)amino)-3-methylbutyl)boronic acid
delanzomib [who-dd]
((1r)-1-(((2s,3r)-3-hydroxy-2-(((6-phenylpyridin-2-yl)carbonyl)amino)-1-oxobutyl)amino)-3-methylbutyl)boronic acid
CS-1624
HY-10454
AKOS022185107
SCHEMBL555047
delanzomib (cep-18770)
((r)-1-((2s,3r)-3-hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutyl)boronic acid
[(1r)-1-[[(2s,3r)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid
AC-24847
delanzomib, free base
J-500001
NCGC00346469-05
DB11956
[(1r)-1-[[(2s,3r)-3-hydroxy-2-[[(6-phenylpyridin-2-yl)carbonyl]amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid.
[(1r)-1-[(2s,3r)-3-hydroxy-2-[(6-phenylpyridin-2-yl)formamido]butanamido]-3-methylbutyl]boronic acid
AMY21646
[(1r)-1-[[(2s,3r)-3-hydroxy-2-[[(6-phenylpyridin-2-yl)carbonyl]amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid
nsc764334
nsc-764334
cep-18770; delanzomib
EX-A2040
Q27264956
F84973
MS-27143
NCGC00346469-08
XIB49927
DTXSID901025656

Research Excerpts

Overview

Delanzomib is an orally active, reversible P2 threonine boronic acid inhibitor of the 26S mammalian proteasome.

ExcerptReferenceRelevance
"Delanzomib (CEP-18770) is an orally active, reversible P2 threonine boronic acid inhibitor of the 26S mammalian proteasome."( Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.
Lu, LD; Ruggeri, BA; Seavey, MM; Stump, KL; Wallace, NH, 2012
)
1.36

Treatment

ExcerptReferenceRelevance
"Delanzomib treatment suppressed the development and progression of renal tissue damage and extended the survival of ill mice."( Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.
Lu, LD; Ruggeri, BA; Seavey, MM; Stump, KL; Wallace, NH, 2012
)
1.36

Compound-Compound Interactions

ExcerptReferenceRelevance
"Preclinical and clinical studies have shown that proteasome inhibitors (PIs) have anti-MM activity in combination with dexamethasone or lenalidomide."( CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
Berenson, JR; Chen, H; Hunter, K; Jones-Bolin, S; Li, J; Li, M; Ruggeri, B; Sanchez, E; Wang, C, 2012
)
0.77

Bioavailability

ExcerptReferenceRelevance
" Herein, the potent, selective, and orally bioavailable threonine-derived 20S human proteasome inhibitor that has been advanced to preclinical development, [(1R)-1-[[(2 S,3 R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid 20 (CEP-18770), is disclosed."( Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
Allievi, C; Ator, MA; Bernardini, R; Bernareggi, A; Cassarà, PG; Chatterjee, S; D'Arasmo, G; De Munari, S; Dorsey, BD; Ferretti, E; Iqbal, M; Mallamo, JP; Menta, E; Oliva, A; Pezzoni, G; Ruggeri, B; Strepponi, I; Williams, M, 2008
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
proteasome inhibitorA drug that blocks the action of proteasomes, cellular complexes that break down proteins.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
threonine derivativeAn amino acid derivative resulting from reaction of threonine at the amino group or the carboxy group, or from the replacement of any hydrogen of threonine by a heteroatom. The definition normally excludes peptides containing threonine residues.
phenylpyridine
C-terminal boronic acid peptideA member of the class of boronic acids that is any peptide in which the carboxy group at the C-terminus has been replaced by a borono (-B(OH)2) group.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fumarate hydrataseHomo sapiens (human)Potency0.13210.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency0.06410.00529.466132.9993AID1347411
EWS/FLI fusion proteinHomo sapiens (human)Potency0.05920.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
polyproteinZika virusPotency0.13210.00308.794948.0869AID1347053
Interferon betaHomo sapiens (human)Potency0.06410.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neutrophil elastaseHomo sapiens (human)IC50 (µMol)3.55000.00632.073422.3780AID316582
Cathepsin GHomo sapiens (human)IC50 (µMol)1.06180.01372.42247.4130AID316535; AID526656
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)3.50000.00011.753610.0000AID316528
Proteasome subunit beta type-1Homo sapiens (human)IC50 (µMol)0.03100.00060.73766.3700AID1604182
ChymaseHomo sapiens (human)IC50 (µMol)3.53000.02602.639710.0000AID316541
Proteasome subunit beta type-8Homo sapiens (human)IC50 (µMol)0.00300.00130.36985.0000AID1604187
Proteasome subunit beta type-9Homo sapiens (human)IC50 (µMol)0.00100.00100.76115.0000AID1604183
Proteasome subunit beta type-5Homo sapiens (human)IC50 (µMol)0.00330.00050.939410.0000AID1604186; AID706738
Proteasome subunit beta type-10Homo sapiens (human)IC50 (µMol)0.01000.00130.81515.0000AID1604185
Proteasome subunit beta type-2Homo sapiens (human)IC50 (µMol)1.80000.00131.39067.9540AID1604184; AID706737
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cathepsin GHomo sapiens (human)EC50 (µMol)0.01350.01350.01350.0135AID526655
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (111)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINeutrophil elastaseHomo sapiens (human)
response to yeastNeutrophil elastaseHomo sapiens (human)
leukocyte migration involved in inflammatory responseNeutrophil elastaseHomo sapiens (human)
biosynthetic process of antibacterial peptides active against Gram-negative bacteriaNeutrophil elastaseHomo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
intracellular calcium ion homeostasisNeutrophil elastaseHomo sapiens (human)
response to UVNeutrophil elastaseHomo sapiens (human)
extracellular matrix disassemblyNeutrophil elastaseHomo sapiens (human)
protein catabolic processNeutrophil elastaseHomo sapiens (human)
response to lipopolysaccharideNeutrophil elastaseHomo sapiens (human)
negative regulation of chemokine productionNeutrophil elastaseHomo sapiens (human)
negative regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
positive regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
defense response to bacteriumNeutrophil elastaseHomo sapiens (human)
positive regulation of MAP kinase activityNeutrophil elastaseHomo sapiens (human)
positive regulation of smooth muscle cell proliferationNeutrophil elastaseHomo sapiens (human)
negative regulation of inflammatory responseNeutrophil elastaseHomo sapiens (human)
positive regulation of immune responseNeutrophil elastaseHomo sapiens (human)
negative regulation of chemotaxisNeutrophil elastaseHomo sapiens (human)
pyroptosisNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of fungusNeutrophil elastaseHomo sapiens (human)
positive regulation of leukocyte tethering or rollingNeutrophil elastaseHomo sapiens (human)
phagocytosisNeutrophil elastaseHomo sapiens (human)
acute inflammatory response to antigenic stimulusNeutrophil elastaseHomo sapiens (human)
proteolysisCathepsin GHomo sapiens (human)
angiotensin maturationCathepsin GHomo sapiens (human)
monocyte chemotaxisCathepsin GHomo sapiens (human)
protein phosphorylationCathepsin GHomo sapiens (human)
proteolysisCathepsin GHomo sapiens (human)
immune responseCathepsin GHomo sapiens (human)
protein processingCathepsin GHomo sapiens (human)
cytokine-mediated signaling pathwayCathepsin GHomo sapiens (human)
protein metabolic processCathepsin GHomo sapiens (human)
antibacterial humoral responseCathepsin GHomo sapiens (human)
extracellular matrix disassemblyCathepsin GHomo sapiens (human)
platelet activationCathepsin GHomo sapiens (human)
purinergic nucleotide receptor signaling pathwayCathepsin GHomo sapiens (human)
neutrophil activationCathepsin GHomo sapiens (human)
positive regulation of immune responseCathepsin GHomo sapiens (human)
defense response to Gram-negative bacteriumCathepsin GHomo sapiens (human)
defense response to Gram-positive bacteriumCathepsin GHomo sapiens (human)
defense response to fungusCathepsin GHomo sapiens (human)
negative regulation of T cell activationCathepsin GHomo sapiens (human)
neutrophil-mediated killing of gram-positive bacteriumCathepsin GHomo sapiens (human)
cellular response to lipopolysaccharideCathepsin GHomo sapiens (human)
biofilm matrix disassemblyCathepsin GHomo sapiens (human)
positive regulation of platelet aggregationCathepsin GHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-1Homo sapiens (human)
proteolysis involved in protein catabolic processProteasome subunit beta type-1Homo sapiens (human)
angiotensin maturationChymaseHomo sapiens (human)
peptide metabolic processChymaseHomo sapiens (human)
extracellular matrix disassemblyChymaseHomo sapiens (human)
protein catabolic processChymaseHomo sapiens (human)
midbrain developmentChymaseHomo sapiens (human)
basement membrane disassemblyChymaseHomo sapiens (human)
positive regulation of angiogenesisChymaseHomo sapiens (human)
regulation of inflammatory responseChymaseHomo sapiens (human)
cellular response to glucose stimulusChymaseHomo sapiens (human)
cytokine precursor processingChymaseHomo sapiens (human)
antigen processing and presentationProteasome subunit beta type-8Homo sapiens (human)
fat cell differentiationProteasome subunit beta type-8Homo sapiens (human)
regulation of endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-8Homo sapiens (human)
immune system processProteasome subunit beta type-9Homo sapiens (human)
regulation of cysteine-type endopeptidase activityProteasome subunit beta type-9Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-9Homo sapiens (human)
proteolysisProteasome subunit beta type-5Homo sapiens (human)
response to oxidative stressProteasome subunit beta type-5Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-5Homo sapiens (human)
cell morphogenesisProteasome subunit beta type-10Homo sapiens (human)
humoral immune responseProteasome subunit beta type-10Homo sapiens (human)
T cell proliferationProteasome subunit beta type-10Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-10Homo sapiens (human)
response to organonitrogen compoundProteasome subunit beta type-2Homo sapiens (human)
response to organic cyclic compoundProteasome subunit beta type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (39)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
protease bindingNeutrophil elastaseHomo sapiens (human)
transcription corepressor activityNeutrophil elastaseHomo sapiens (human)
endopeptidase activityNeutrophil elastaseHomo sapiens (human)
serine-type endopeptidase activityNeutrophil elastaseHomo sapiens (human)
protein bindingNeutrophil elastaseHomo sapiens (human)
heparin bindingNeutrophil elastaseHomo sapiens (human)
peptidase activityNeutrophil elastaseHomo sapiens (human)
cytokine bindingNeutrophil elastaseHomo sapiens (human)
serine-type endopeptidase activityCathepsin GHomo sapiens (human)
protein bindingCathepsin GHomo sapiens (human)
heparin bindingCathepsin GHomo sapiens (human)
peptidase activityCathepsin GHomo sapiens (human)
serine-type peptidase activityCathepsin GHomo sapiens (human)
receptor ligand activityCathepsin GHomo sapiens (human)
caspase bindingCathepsin GHomo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
protein bindingProteasome subunit beta type-1Homo sapiens (human)
endopeptidase activityChymaseHomo sapiens (human)
serine-type endopeptidase activityChymaseHomo sapiens (human)
serine-type peptidase activityChymaseHomo sapiens (human)
peptide bindingChymaseHomo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
protein bindingProteasome subunit beta type-8Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-9Homo sapiens (human)
protein bindingProteasome subunit beta type-9Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-9Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
protein bindingProteasome subunit beta type-5Homo sapiens (human)
peptidase activityProteasome subunit beta type-5Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-10Homo sapiens (human)
protein bindingProteasome subunit beta type-10Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-10Homo sapiens (human)
protein bindingProteasome subunit beta type-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
extracellular regionNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
cytoplasmNeutrophil elastaseHomo sapiens (human)
cytosolNeutrophil elastaseHomo sapiens (human)
cell surfaceNeutrophil elastaseHomo sapiens (human)
secretory granuleNeutrophil elastaseHomo sapiens (human)
azurophil granule lumenNeutrophil elastaseHomo sapiens (human)
specific granule lumenNeutrophil elastaseHomo sapiens (human)
phagocytic vesicleNeutrophil elastaseHomo sapiens (human)
collagen-containing extracellular matrixNeutrophil elastaseHomo sapiens (human)
extracellular exosomeNeutrophil elastaseHomo sapiens (human)
transcription repressor complexNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
collagen-containing extracellular matrixCathepsin GHomo sapiens (human)
extracellular regionCathepsin GHomo sapiens (human)
extracellular spaceCathepsin GHomo sapiens (human)
nucleusCathepsin GHomo sapiens (human)
lysosomeCathepsin GHomo sapiens (human)
cytosolCathepsin GHomo sapiens (human)
plasma membraneCathepsin GHomo sapiens (human)
cytoplasmic stress granuleCathepsin GHomo sapiens (human)
membraneCathepsin GHomo sapiens (human)
secretory granuleCathepsin GHomo sapiens (human)
azurophil granule lumenCathepsin GHomo sapiens (human)
collagen-containing extracellular matrixCathepsin GHomo sapiens (human)
extracellular exosomeCathepsin GHomo sapiens (human)
cytoplasmCathepsin GHomo sapiens (human)
intracellular membrane-bounded organelleCathepsin GHomo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
nucleusProteasome subunit beta type-1Homo sapiens (human)
cytoplasmProteasome subunit beta type-1Homo sapiens (human)
proteasome complexProteasome subunit beta type-1Homo sapiens (human)
extracellular regionProteasome subunit beta type-1Homo sapiens (human)
nucleusProteasome subunit beta type-1Homo sapiens (human)
nucleoplasmProteasome subunit beta type-1Homo sapiens (human)
cytosolProteasome subunit beta type-1Homo sapiens (human)
secretory granule lumenProteasome subunit beta type-1Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-1Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit beta type-1Homo sapiens (human)
proteasome core complexProteasome subunit beta type-1Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-1Homo sapiens (human)
collagen-containing extracellular matrixChymaseHomo sapiens (human)
extracellular regionChymaseHomo sapiens (human)
cytosolChymaseHomo sapiens (human)
secretory granuleChymaseHomo sapiens (human)
cytoplasmic ribonucleoprotein granuleChymaseHomo sapiens (human)
collagen-containing extracellular matrixChymaseHomo sapiens (human)
extracellular spaceChymaseHomo sapiens (human)
intracellular membrane-bounded organelleChymaseHomo sapiens (human)
cytoplasmChymaseHomo sapiens (human)
nucleoplasmProteasome subunit beta type-8Homo sapiens (human)
cytosolProteasome subunit beta type-8Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-8Homo sapiens (human)
proteasome complexProteasome subunit beta type-8Homo sapiens (human)
proteasome core complexProteasome subunit beta type-8Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-8Homo sapiens (human)
spermatoproteasome complexProteasome subunit beta type-8Homo sapiens (human)
nucleusProteasome subunit beta type-8Homo sapiens (human)
cytosolProteasome subunit beta type-8Homo sapiens (human)
nucleoplasmProteasome subunit beta type-9Homo sapiens (human)
cytosolProteasome subunit beta type-9Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-9Homo sapiens (human)
proteasome complexProteasome subunit beta type-9Homo sapiens (human)
proteasome core complexProteasome subunit beta type-9Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-9Homo sapiens (human)
spermatoproteasome complexProteasome subunit beta type-9Homo sapiens (human)
cytosolProteasome subunit beta type-9Homo sapiens (human)
nucleusProteasome subunit beta type-9Homo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
cytoplasmProteasome subunit beta type-5Homo sapiens (human)
proteasome complexProteasome subunit beta type-5Homo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
nucleoplasmProteasome subunit beta type-5Homo sapiens (human)
centrosomeProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-5Homo sapiens (human)
proteasome core complexProteasome subunit beta type-5Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
nucleoplasmProteasome subunit beta type-10Homo sapiens (human)
cytosolProteasome subunit beta type-10Homo sapiens (human)
proteasome complexProteasome subunit beta type-10Homo sapiens (human)
proteasome core complexProteasome subunit beta type-10Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-10Homo sapiens (human)
spermatoproteasome complexProteasome subunit beta type-10Homo sapiens (human)
cytosolProteasome subunit beta type-10Homo sapiens (human)
nucleusProteasome subunit beta type-10Homo sapiens (human)
nucleusProteasome subunit beta type-2Homo sapiens (human)
cytoplasmProteasome subunit beta type-2Homo sapiens (human)
proteasome complexProteasome subunit beta type-2Homo sapiens (human)
nucleusProteasome subunit beta type-2Homo sapiens (human)
nucleoplasmProteasome subunit beta type-2Homo sapiens (human)
cytosolProteasome subunit beta type-2Homo sapiens (human)
membraneProteasome subunit beta type-2Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-2Homo sapiens (human)
proteasome core complexProteasome subunit beta type-2Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-2Homo sapiens (human)
cytosolProteasome subunit beta type-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (149)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID316501Cytotoxicity against human A2780 cells2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316559Inhibition of human caspase 9 at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID706738Reversible inhibition of human erythrocyte derived 20S proteasome subunit beta5 after 30 mins by fluorogenic assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Molecular mechanisms of acquired proteasome inhibitor resistance.
AID1604183Inhibition of 20S proteasome beta 1i (unknown origin) after 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID526656Inhibition of cathepsin G2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
AID316503AUC (0 to infinity) in Sprague-Dawley rat at 0.2 mg/kg, iv2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316570Inhibition of human tryptase at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316566Inhibition of human renin at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID526658Oral bioavailability in mouse2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
AID316555Inhibition of human caspase 2 at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316531Inhibition of bovine cathepsin C at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316544Inhibition of human factor 7a at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316524Inhibition of human recombinant CYP1A2 upto 30 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316549Inhibition of human MMP2 at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316547Inhibition of human plasma kallikrein at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316582Inhibition of human neutrophil elastase 22008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316580Protein binding in dog plasma2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316561Inhibition of human ECE1 at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID1604184Inhibition of 20S proteasome beta 2c (unknown origin) after 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID316567Inhibition of human thrombin at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316511Volume of distribution at steady state in CD1 mouse at 4 mg/kg, iv2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316528Inhibition of human recombinant CYP3A42008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316558Inhibition of human caspase 8 at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316506Half life in Sprague-Dawley rat at 0.8 mg/kg, po2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316538Inhibition of human cathepsin S at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316509Half life in CD1 mouse at 4 mg/kg, iv2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316554Inhibition of human caspase 1 at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316504Volume of distribution at steady state in Sprague-Dawley rat at 0.2 mg/kg, iv2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316568Inhibition of human TPA at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316499Inhibition of bovine alpha chymotrypsin2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316507AUC (0 to infinity) in Sprague-Dawley rat at 0.8 mg/kg, po2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID706737Reversible inhibition of human erythrocyte derived 20S proteasome subunit beta2 after 30 mins by fluorogenic assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Molecular mechanisms of acquired proteasome inhibitor resistance.
AID316536Inhibition of human cathepsin H at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316543Inhibition of human chymotrypsin2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316573Inhibition of human TACE at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316552Inhibition of human MMP8 at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316575Metabolic stability in rat liver microsomes2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID1604185Inhibition of 20S proteasome beta 2i (unknown origin) after 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID316571Inhibition of human neutrophil elastase 2 at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316529Inhibition of human calpain 1 at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316540Inhibition of human chymase at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316527Inhibition of human recombinant CYP2D6 upto 30 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316545Inhibition of human factor 10a at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316541Inhibition of human chymase2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316530Inhibition of human cathepsin B at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316514AUC (0 to infinity) in CD1 mouse at 10 mg/kg, po2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID526655Inhibition of cathepsin G in human MOLT4 cells2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
AID316515Oral bioavailability in CD1 mouse at 10 mg/kg2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316500Inhibition of chymotrypsin-like activity of human 20S proteasome in Molt4 cells2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID1604182Inhibition of 20S proteasome beta 1c (unknown origin) after 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID316569Inhibition of human trypsin at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316563Inhibition of pig pepsin at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID1461482Inhibition of chymotrypsin-like activity of 20S proteasome in rabbit 20S proteasome pre-incubated for 10 mins before Suc-Leu-Leu-Val-Tyr-AMC substrate addition and measured after 2 hrs by fluorescence assay2017Bioorganic & medicinal chemistry, 10-01, Volume: 25, Issue:19
Azobenzene-containing photoswitchable proteasome inhibitors with selective activity and cellular toxicity.
AID526657Oral bioavailability in rat2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
AID316508Oral bioavailability in Sprague-Dawley rat at 0.8 mg/kg2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316562Inhibition of human NEP at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316510AUC (0 to infinity) in CD1 mouse at 4 mg/kg, iv2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316513Half life in CD1 mouse at 10 mg/kg, po2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID1604186Inhibition of 20S proteasome beta 5c (unknown origin) after 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID316505Clearance in Sprague-Dawley rat at 0.2 mg/kg, iv2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316572Inhibition of pig pancreatic elastase 1 at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316502Half life in Sprague-Dawley rat at 0.2 mg/kg, iv2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316556Inhibition of human caspase 3 at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316539Inhibition of human cathepsin Z at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316550Inhibition of human MMP3 at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316523Inhibition of 20S proteasome beta5beta1 subunit binding in human RPMI 8226 cells xenografted mouse2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID1128233Inhibition of caspase-like activity of proteasome (unknown origin)2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.
AID316574Metabolic stability in mouse liver microsomes2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316525Inhibition of human recombinant CYP2C9 upto 30 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316533Inhibition of human cathepsin E at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID1604189Selectivity index, ratio of IC50 for 20S proteasome beta 2c (unknown origin) to IC50 for 20S proteasome beta 2i (unknown origin)2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID316546Inhibition of HIV1 protease at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316498Inhibition of chymotrypsin-like activity of human erythrocyte 20S proteasome2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID1604187Inhibition of 20S proteasome beta 5i (unknown origin) after 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID316578Protein binding in mouse plasma2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316526Inhibition of human recombinant CYP2C19 upto 30 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316557Inhibition of human caspase 7 at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316564Inhibition of bacterial prolyl oligopeptidase at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316534Inhibition of human cathepsin G at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID1461483Inhibition of caspase-like activity of 20S proteasome in rabbit 20S proteasome pre-incubated for 10 mins before Suc-Leu-Leu-Val-Tyr-AMC substrate addition and measured after 2 hrs by fluorescence assay2017Bioorganic & medicinal chemistry, 10-01, Volume: 25, Issue:19
Azobenzene-containing photoswitchable proteasome inhibitors with selective activity and cellular toxicity.
AID316565Inhibition of human plasmin at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316577Metabolic stability in human liver microsomes2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316542Inhibition of human chymotrypsin at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316535Inhibition of human cathepsin G2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316581Protein binding in human plasma2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316548Inhibition of human MMP1 at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316560Inhibition of human DPP4 at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316579Protein binding in rat plasma2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316512Clearance in CD1 mouse at 4 mg/kg, iv2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316553Inhibition of human MMP12 at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316551Inhibition of human MMP7 at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316537Inhibition of human cathepsin L at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316576Metabolic stability in dog liver microsomes2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID316532Inhibition of human cathepsin D at 10 uM2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (5.41)29.6817
2010's26 (70.27)24.3611
2020's9 (24.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.97 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index5.30 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.70%)5.53%
Reviews8 (21.62%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (75.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy [NCT01023880]Phase 1/Phase 262 participants (Actual)Interventional2010-01-31Terminated
An Open-Label, Dose-escalation, Phase I Study to Determine the Maximum Tolerated Dose, Recommended Dose, Pharmacokinetics, and Pharmacodynamics of the Proteosome Inhibitor CEP 18770 Given Intravenously as Single Agent in Patients With Advanced Solid Tumou [NCT00572637]Phase 155 participants (Anticipated)Interventional2007-11-30Completed
An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy of CEP-18770 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [NCT01348919]Phase 1/Phase 211 participants (Actual)Interventional2011-08-03Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01348919 (8) [back to overview]Duration of Response (DOR) for Participants Treated With CEP-18770 at the MTD, as Assessed Using IMWG Criteria
NCT01348919 (8) [back to overview]Maximum Tolerated Dose of CEP-18770
NCT01348919 (8) [back to overview]Number of Participants With Adverse Events (AEs)
NCT01348919 (8) [back to overview]Overall Response Rate (ORR) in Participants Treated at the (Maximum Tolerated Dose) MTD, as Assessed Using International Myeloma Working Group (IMWG) Criteria
NCT01348919 (8) [back to overview]Time to Progression (TTP) for Participants Treated With CEP-18770 at the MTD, as Assessed Using IMWG Criteria
NCT01348919 (8) [back to overview]Area Under the Plasma Concentration-Time Curve From Time 0 to t (AUC0-t) of CEP-18770
NCT01348919 (8) [back to overview]Maximum Observed Plasma Concentration (Cmax) of CEP-18770
NCT01348919 (8) [back to overview]Time to Reach Cmax (Tmax) of CEP-18770

Duration of Response (DOR) for Participants Treated With CEP-18770 at the MTD, as Assessed Using IMWG Criteria

DOR was defined as the time interval from the date of first response (sCR, CR, VGPR, or PR) to the date of disease progression. sCR, CR, VGPR, and PR as defined in outcome measure 1. Disease progression was defined as any 1 or more of the following: Increase of 25% or more from lowest response level in any 1 or more of the following: - serum M-component (absolute increase must be ≥0.5 grams [g]/deciliter [dL]), - urine M-component (absolute increase must be ≥200 mg/24 hours), bone marrow plasma cell percentage ≥10%; definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; and development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that could be attributed solely to the plasma cell proliferation disorder. (NCT01348919)
Timeframe: From the date of first response to the date of disease progression (up to approximately 1.5 years)

Interventionmonths (Median)
CEP-18770 Dose BNA

[back to top]

Maximum Tolerated Dose of CEP-18770

MTD was based on the assessment of dose-limiting toxicity (DLT) during cycle 1 only and was defined as the highest dose at which fewer than one-third of participants in a cohort experience DLT. A DLT was defined as any of the following drug-related toxicities occurring during Cycle 1: Hematologic adverse events (AEs) (Grade 4 hematologic AEs, Grade 3 hematologic AEs with sequelae); Grade 3 nonhematologic AEs; Neuropathy (Grade 2 neuropathy, Grade 1 neuropathy with pain, worsening grade of neuropathy or new symptoms of pain associated with neuropathy); Any other toxicity that, in the judgment of the principal investigator, was a DLT; If a participant cannot receive 75% of the planned dose for any of the 3 agents (missing >1 dose of CEP-18770, or >5 doses of lenalidomide, or >1 dose of dexamethasone [either consecutively or separately]), due to a drug-related AE, the event was considered a DLT, even if the grade of toxicity was lower than specified DLT determination as described above. (NCT01348919)
Timeframe: Cycle 1 (28 days)

Interventionmg/m^2 (Number)
Overall Population1.8

[back to top]

Number of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. (NCT01348919)
Timeframe: From the first administration of CEP-18770 up to approximately 1.5 years

InterventionParticipants (Count of Participants)
CEP-18770 Dose A3
CEP-18770 Dose B5
CEP-18770 Dose C3

[back to top]

Overall Response Rate (ORR) in Participants Treated at the (Maximum Tolerated Dose) MTD, as Assessed Using International Myeloma Working Group (IMWG) Criteria

The ORR is defined as percentage of participants who achieve a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) during the study. sCR: negative immunofixation in serum and urine; disappearance of any soft tissue plasmacytomas; < 5% plasma cells in bone marrow; normal free light chain (FLC) ratio; and absence of clonal cells in bone marrow. CR: negative immunofixation in serum and urine; disappearance of any soft tissue plasmacytomas; and <5% plasma cells in bone marrow. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis; 90% or greater reduction in serum M-protein level and urine M-protein level less than 100 milligrams (mg)/24 hours. PR: ≥50% reduction in serum M-protein level; ≥90% reduction in 24-hour urinary M-protein level or reduction to less than 200 mg per 24 hours; and ≥50% reduction in the size of any soft tissue plasmacytomas present at baseline. (NCT01348919)
Timeframe: From the first administration of CEP-18770 up to approximately 1.5 years

Interventionpercentage of participants (Number)
CEP-18770 Dose B40

[back to top]

Time to Progression (TTP) for Participants Treated With CEP-18770 at the MTD, as Assessed Using IMWG Criteria

TTP was defined as the time interval from the date of first dose to the date of disease progression. Disease progression was defined as any 1 or more of the following: Increase of 25% or more from lowest response level in any 1 or more of the following: - serum M-component (absolute increase must be ≥0.5 g/dL), - urine M-component (absolute increase must be ≥200 mg/24 hours), bone marrow plasma cell percentage ≥10%; definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; and development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that could be attributed solely to the plasma cell proliferation disorder. (NCT01348919)
Timeframe: From the date of first dose of study drug to the date of disease progression (up to approximately 1.5 years)

Interventionmonths (Median)
CEP-18770 Dose BNA

[back to top]

Area Under the Plasma Concentration-Time Curve From Time 0 to t (AUC0-t) of CEP-18770

(NCT01348919)
Timeframe: Before and immediately after end of infusion (EOI) and at approximately 2, 4, and 8 hours after the EOI on Days 1 and 15 of Cycle 1

,,
Interventionng*hours/mL (Mean)
Day 1Day 15
CEP-18770 Dose A6731595
CEP-18770 Dose B13712071
CEP-18770 Dose C15272266

[back to top]

Maximum Observed Plasma Concentration (Cmax) of CEP-18770

(NCT01348919)
Timeframe: Before and immediately after end of infusion (EOI) and at approximately 2, 4, and 8 hours after the EOI on Days 1 and 15 of Cycle 1

,,
Interventionnanograms (ng)/ milliliter (mL) (Mean)
Day 1Day 15
CEP-18770 Dose A579.49639.59
CEP-18770 Dose B663.00628.07
CEP-18770 Dose C876.97977.09

[back to top]

Time to Reach Cmax (Tmax) of CEP-18770

(NCT01348919)
Timeframe: Before and immediately after end of infusion (EOI) and at approximately 2, 4, and 8 hours after the EOI on Days 1 and 15 of Cycle 1

,,
Interventionhours (Median)
Day 1Day 15
CEP-18770 Dose A0.070.07
CEP-18770 Dose B0.080.08
CEP-18770 Dose C0.100.08

[back to top]